Search

Your search keyword '"Zárate-Rodríguez, Pedro A."' showing total 2 results
Start Over Author "Zárate-Rodríguez, Pedro A." Publisher unidad de congresos del centro medico nacional
2 results on '"Zárate-Rodríguez, Pedro A."'

1. Consensus in acute myeloid leukemia in Mexico.

Author

Arana-Luna LL, Alvarado-Ibarra M, Silva-Michel LG, Morales-Maravilla A, González-Rubio MDC, Chávez-Aguilar LA, Tena-Iturralde MF, Mojica-Balceras L, Zapata-Canto N, Galindo-Delgado P, Miranda-Madrazo MR, Morales-Hernández AE, Silva-Vera K, Grimaldo-Gómez FA, Hernández-Caballero Á, Bates-Martin RA, Álvarez-Vera JL, Tepepa-Flores F, Teomitzi-Sánchez Ó, Fermín-Caminero DJ, Peña-Celaya JA, Salazar-Ramírez Ó, Flores-Villegas LV, Guerra-Alarcón LV, Leyto-Cruz F, Inclán-Alarcón SI, Milán-Salvatierra AI, Ventura-Enríquez Y, Pérez-Lozano U, Báez-Islas PE, Tapia-Enríquez AL, Palma-Moreno OG, Aguilar-Luévano J, Espinosa-Partida A, Pérez-Jacobo LF, Rojas-Castillejos F, Ruiz-Contreras JI, Loera-Fragoso SJ, Medina-Coral JE, Acosta-Maldonado BL, Soriano-Mercedes EJ, Saucedo-Montes EE, Valero-Saldana LM, González-Prieto SG, Nava-Villegas L, Hernández-Colin AK, Hernández-Alcántara AE, Zárate-Rodríguez PA, Ignacio-Ibarra G, Meillón-García LA, Espinosa-Bautista KA, Cruz CL, Barbosa-Loría DM, García-Castillo C, Balderas-Delgado C, Cabrera-García Á, Pérez-Zúñiga JM, Hernández-Ruiz E, Villela-Peña A, Cortés SCG, Romero-Rodelo H, Garzón-Velásquez KB, Serrano-Hernández C, Martínez-Ríos A, Pedraza-Solís ML, Martínez-Coronel JA, Narváez-Davalos IM, García-Camacho AS, Merino-Pasaye LE, Aguilar-Andrade C, Aguirre-Domínguez JA, Guzmán-Mera PG, Rosa ED, López PEF, González-Aguirre LL, Ramírez-Alfaro EM, Vera-Calderón H, Meza-Dávalos ML, Murillo-Cruz J, Pichardo-Cepín YM, and Ramírez-Romero EF

Subjects
Cell Differentiation, Consensus, Humans, Mexico, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute therapy
Abstract

Acute myeloid leukemia (AML) comprises a heterogeneous group of hematopoietic cell neoplasms of myeloid lineage that arise from the clonal expansion of their precursors in the bone marrow, interfering with cell differentiation, leading to a syndrome of bone marrow failure. AML is a consequence of genetic and epigenetic changes (point mutations, gene rearrangements, deletions, amplifications, and arrangements in epigenetic changes that influence gene expression) in hematopoietic precursor cells, which create a clone of abnormal cells that are capable of proliferating but cannot differentiate into mature hematopoietic cells or undergo programmed cell death. The diagnosis requires more than 20% myeloid blasts in the bone marrow and certain cytogenic abnormalities. Treatment will depend on age, comorbidities, and cytogenetic risk among the most frequent., (Copyright: © 2022 Permanyer.)

Published
2022
Full Text
View/download PDF

2. Mexican Concensus of Multiple Myeloma.

Author

de la Peña-Celaya JA, Aguilar-Luevano J, Alcivar-Cedeño LM, Álvarez-Vera JL, Anaya-Cuellar I, Añorve-Hernández E, Arana-Luna LL, Arteaga-Ortíz L, Báez-Islas PE, Banda-García LI, Bates-Martín RA, Campa-Monroy DI, Cardiel-Silva M, Castillo-Salas ÁJ, Cota-Rangel X, Díaz-Vargas G, Espitia-Ríos ME, Estrada-Domínguez P, Fermín-Caminero D, García-Camacho A, García-Castillo C, Garzón-Velásquez KB, Gil-Rondero C, Guerra-Alarcón LV, Hernández-Colín AK, Hernández-Ruiz E, Hernández-Alcántara AE, Hernández-Cervantes SA, Herrera-Olivares W, Ignacio-Ibarra G, Inclán-Alarcón SI, Leyto-Cruz F, Macías-Flores JP, Vega AM, Martínez-Ramírez MA, Martínez-Coronel J, Medina-Coral JE, Meza-Dávalos L, Montoya-Jiménez L, Morales-Hernández A, Morales-López E, Morales-Adrián JJ, Azcué MM, Mújica-Martínez A, Murillo-Cruz JL, Nájera-Martínez J, Narváez-Sarmiento IM, Nava-Villegas L, Nava-Alpide MA, Orellana Garibay JJ, Palafox-Zaldívar MT, Palma-Moreno OG, Paredes-Lozano EP, Pedraza-Colín ML, Pérez-Zúñiga JM, Pérez-Lizardi AB, Rojas-Castillejos F, Romero-Martínez E, Romero-Rodelo H, Ruiz-Contreras J, Saavedra-González A, Saucedo-Montes E, Silva-Michel LG, Silva-Vera K, Teomitzi-Sánchez Ó, Tepepa-Flores F, Ventura-Enríquez Y, Villela-Peña A, Vilchis-González SP, Zapata-Canto N, Zárate-Rodríguez PA, and Alvarado-Ibarra M

Subjects
Algorithms, Humans, Mexico, Multiple Myeloma complications, Multiple Myeloma diagnosis, Multiple Myeloma therapy
Abstract

To identify this increasingly common pathology, known as multiple myeloma (MM), it is necessary to refer to the specific factors that characterize it; to this end, the classic criteria known as CRAB (hyperkalemia, renal failure, anemia, and lytic lesions) are available, in which renal failure is one of the most frequent complications. Recently, three indisputable biomarkers have been described for the diagnostic support for MM, which are: more than 10% of clonal plasma cells in bone marrow or, a biopsy that corroborates the presence of a plasmacytoma, light chain ratio ≥ 100 mg/dL and more than one focal lesion on magnetic resonance imaging. A differential diagnosis for plasma cell leukemia, solitary bone plasmacytoma, and extramedullary plasmacytoma should always be considered. Being this an incurable disease, a lot of research has been done regarding its therapeutic management, whose main objective is the disappearance of plasma cells and the patient clinical improvement. Melphalan was the first drug that showed a benefit in 1958 and afterward, with the addition of a steroid as a second drug, it was possible to improve response rates. Subsequently, different molecules were studied, forming multiple combinations, and achieving better rates of overall survival and progression-free survival. Years later, with the arrival of proteasome inhibitors such as bortezomib, and immunomodulators such as thalidomide and lenalidomide, an important turnaround in the disease has been seen, as deeper responses, more prolonged remissions, and improvement in the quality of life of patients have been achieved. This consensus has the purpose of integrating a group of Mexican specialists and promoting the updating of this pathology., (Copyright: © 2020 Permanyer.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results